Study: NCT03103399

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comtan®
Description: 200 mg entacapone were to be taken concomitantly with each levodopa/DDCI dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebicapone
Description: 50 mg, 100 mg and 150 mg doses of nebicapone were to be taken concomitantly with each levodopa/DDCI dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebicapone
Description: 50 mg, 100 mg and 150 mg doses of nebicapone were to be taken concomitantly with each levodopa/DDCI dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebicapone
Description: 50 mg, 100 mg and 150 mg doses of nebicapone were to be taken concomitantly with each levodopa/DDCI dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa/DDCI
Description: Prior to the study, all patients were to have been receiving levodopa/DDCI therapy for at least 1 year with clear clinical improvement. At entry to the study, patients were to be receiving levodopa/DDCI therapy of at least 4 but not more than 8 (inclusive) standard daily doses.~All patients were to continue receiving levodopa/DDCI during the study. Levodopa and DDCI were prescribed by the investigators and purchased locally by patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa/DDCI
Description: Prior to the study, all patients were to have been receiving levodopa/DDCI therapy for at least 1 year with clear clinical improvement. At entry to the study, patients were to be receiving levodopa/DDCI therapy of at least 4 but not more than 8 (inclusive) standard daily doses.~All patients were to continue receiving levodopa/DDCI during the study. Levodopa and DDCI were prescribed by the investigators and purchased locally by patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa/DDCI
Description: Prior to the study, all patients were to have been receiving levodopa/DDCI therapy for at least 1 year with clear clinical improvement. At entry to the study, patients were to be receiving levodopa/DDCI therapy of at least 4 but not more than 8 (inclusive) standard daily doses.~All patients were to continue receiving levodopa/DDCI during the study. Levodopa and DDCI were prescribed by the investigators and purchased locally by patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa/DDCI
Description: Prior to the study, all patients were to have been receiving levodopa/DDCI therapy for at least 1 year with clear clinical improvement. At entry to the study, patients were to be receiving levodopa/DDCI therapy of at least 4 but not more than 8 (inclusive) standard daily doses.~All patients were to continue receiving levodopa/DDCI during the study. Levodopa and DDCI were prescribed by the investigators and purchased locally by patients.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levodopa/DDCI
Description: Prior to the study, all patients were to have been receiving levodopa/DDCI therapy for at least 1 year with clear clinical improvement. At entry to the study, patients were to be receiving levodopa/DDCI therapy of at least 4 but not more than 8 (inclusive) standard daily doses.~All patients were to continue receiving levodopa/DDCI during the study. Levodopa and DDCI were prescribed by the investigators and purchased locally by patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally as encapsulated tablets, which were identical in appearance to the study drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally as encapsulated tablets, which were identical in appearance to the study drugs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered orally as encapsulated tablets, which were identical in appearance to the study drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally as encapsulated tablets, which were identical in appearance to the study drugs

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally as encapsulated tablets, which were identical in appearance to the study drugs